{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:16:02Z","timestamp":1794370562220,"version":"4.9.0"},"reference-count":49,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,11,11]],"date-time":"2005-11-11T00:00:00Z","timestamp":1131667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:p>\n                    Antimuscarinic agents are the predominant pharmacological treatment for patients with overactive bladder (OAB). These drugs are thought to act primarily through antagonism at muscarinic M\n                    <jats:sub>3<\/jats:sub>\n                    receptors located at neuromuscular junctions in the human bladder detrusor muscle. Several of these drugs have been shown to be efficacious in ameliorating the symptoms of OAB in older patients, but most currently available agents lack selectivity for the M\n                    <jats:sub>3<\/jats:sub>\n                    receptor subtype, and interaction with other muscarinic receptor subtypes throughout the body may adversely affect a variety of physiological functions and result in unwanted side effects, including cognitive dysfunction. With the recent availability of antimuscarinic agents that show increased selectivity for M\n                    <jats:sub>3<\/jats:sub>\n                    receptors relative to other muscarinic subtypes, an invitational expert panel meeting was convened to review not only the mechanisms by which antimuscarinic agents could affect cognitive function, but also the published literature on cognitive adverse events. A review of the literature shows that the cholinergic system in the central nervous system (CNS) exerts a major influence on cognitive processes, in particular memory via M\n                    <jats:sub>1<\/jats:sub>\n                    cholinergic receptors. In addition, recent evidence suggests a role for M\n                    <jats:sub>2<\/jats:sub>\n                    receptors in mediating cognitive function. Thus, cognitive dysfunction (including memory loss) during treatment with nonselective antimuscarinic agents for OAB is of growing concern, particularly in older patients and those with mild cognitive impairment or dementia. Increased blood\u2013brain barrier permeability, which can occur with advanced age and certain comorbidities, may also facilitate CNS access of antimuscarinic agents (regardless of their physiochemical properties) and add to antimuscarinic burden. On the basis of available evidence, antimuscarinic agents with selectivity for M\n                    <jats:sub>3<\/jats:sub>\n                    over M\n                    <jats:sub>1<\/jats:sub>\n                    and M\n                    <jats:sub>2<\/jats:sub>\n                    receptors, limited CNS penetration, or both may therefore offer a favorable balance of efficacy in treating OAB together with a reduced risk of adverse cognitive events in the older population.\n                  <\/jats:p>","DOI":"10.1111\/j.1532-5415.2005.00537.x","type":"journal-article","created":{"date-parts":[[2005,11,11]],"date-time":"2005-11-11T04:51:14Z","timestamp":1131684674000},"page":"2195-2201","source":"Crossref","is-referenced-by-count":201,"title":["Antimuscarinic Drugs for Overactive Bladder and Their Potential Effects on Cognitive Function in Older Patients"],"prefix":"10.1111","volume":"53","author":[{"given":"Gary G.","family":"Kay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed B.","family":"Abou\u2010Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William S.","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Ouslander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,11,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032662"},{"key":"e_1_2_6_3_2","first-page":"5","article-title":"The effects of antimuscarinic treatments in overactive bladder","volume":"48","author":"Chapple C","year":"2005","journal-title":"A systematic review and meta-analysis"},{"key":"e_1_2_6_4_2","volume-title":"Incontinence. Proceedings of the 3rd International Consultation on Incontinence","author":"Abrams P","year":"2005"},{"key":"e_1_2_6_5_2","unstructured":"Enablex [on\u2010line]. Available athttp:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/enablex.pdfAccessed September 15 2005."},{"key":"e_1_2_6_6_2","unstructured":"NapierC GuptaP.Darifenacin is selective for the human recombinant M3receptor subtype. Presented as a non\u2010discussion poster at the meeting of the International Continence Society Heidelberg Germany 2002 [abstract A445]. Available athttp:\/\/www.continet.org\/publications\/2002\/pdf\/445.pdf"},{"key":"e_1_2_6_7_2","unstructured":"Ditropan\/Ditropan XL [on\u2010line]. Available athttp:\/\/www.orthomcneil.com\/products\/pi\/pdfs\/Lg%20Ditropan%20PI.pdfandhttp:\/\/www.orthomcneil.com\/products\/pi\/pdfs\/ditropanxl.pdfAccessed September 15 2005."},{"key":"e_1_2_6_8_2","unstructured":"VESIcare [on\u2010line]. Available athttp:\/\/www.vesicare.com\/pdf\/vesicare_prescribing_info.pdfAccessed September 15 2005."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-002-0554-x"},{"key":"e_1_2_6_10_2","unstructured":"Detrol LA [on\u2010line]. Available athttp:\/\/www.detrolla.com\/files\/DetrolLA.pdfAccessed September 20 2005."},{"key":"e_1_2_6_11_2","unstructured":"Sanctura [on\u2010line]. Available athttp:\/\/www.sanctura.com\/Sanctura_Prescribing_Information.pdfAccessed September 15 2005."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(03)45003-6"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00581-5"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2680.2001.00231.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb042458"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040223"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245172"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(90)90407-Z"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn992"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550160091022"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3581-04.2004"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10639"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(02)00067-2"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/35065604"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-05-01709.2002"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.261583798"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-6080(02)00059-X"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010528"},{"key":"e_1_2_6_30_2","first-page":"314","article-title":"Age and sex as factors modifying the function of the blood\u2013cerebrospinal fluid barrier","volume":"6","author":"Pakulski C","year":"2000","journal-title":"Med Sci Monit"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.1.70"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/15287390490264802"},{"key":"e_1_2_6_33_2","unstructured":"SkerjanecA DevineniD.Affinity of Darifenacin for the P\u2010Glycoprotein Efflux Pump: A Mechanism Contributing to the CNS Sparing Profile? [Abstract C026]. Presented at the British Pharmacological Society Meeting. Newcastle UK December 14\u201316 2004."},{"key":"e_1_2_6_34_2","first-page":"72","article-title":"Everyday memory performance across the life span","volume":"7","author":"West RL","year":"1992","journal-title":"Effects of age and noncognitive individual differences"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490270418"},{"key":"e_1_2_6_36_2","first-page":"198","article-title":"Serum anticholinergic activity in a community\u2010based sample of older adults","volume":"60","author":"Mulsant BH","year":"2003","journal-title":"Relationship with cognitive performance"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/57.3.M173"},{"key":"e_1_2_6_38_2","first-page":"1393","article-title":"Anticholinergic effects of drugs commonly prescribed for the elderly","volume":"149","author":"Tune L","year":"1992","journal-title":"Potential means for assessing risk of delirium"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.3.3.314"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50281.x"},{"key":"e_1_2_6_41_2","first-page":"2082","article-title":"The concurrent use of anticholinergics and cholinesterase inhibitors","volume":"52","author":"Carnahan RM","year":"2004","journal-title":"Rare event or common practice?"},{"key":"e_1_2_6_42_2","first-page":"771","article-title":"Tolterodine and memory","volume":"60","author":"Womack KB","year":"2003","journal-title":"Dry but forgetful"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200312043492325"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200323060-00003"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05296.x"},{"key":"e_1_2_6_46_2","first-page":"590","article-title":"[Neuropsychiatric adverse effects attributed to use of oxybutynin.]","volume":"142","author":"T'Veld BA","year":"1998","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1363"},{"key":"e_1_2_6_48_2","first-page":"8","article-title":"Identification of medications that cause cognitive impairment in older people","volume":"46","author":"Katz IR","year":"1998","journal-title":"The case of oxybutynin chloride"},{"key":"e_1_2_6_49_2","first-page":"493","article-title":"Assessment of cognitive function of the elderly population","volume":"173","author":"Lipton RB","year":"2005","journal-title":"Effects of darifenacin"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05745.x"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-5415.2005.00537.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-5415.2005.00537.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T19:01:25Z","timestamp":1762196485000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-5415.2005.00537.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,11]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1111\/j.1532-5415.2005.00537.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1532-5415.2005.00537.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,11]]}}}